Insulin Injection Pen Market Size, Share, Growth, and Industry Analysis, By Type (Disposable Insulin Injection pen, Reusable Insulin Injection Pen), By Application (Hospital & Clinic, Retail Pharmacies, Online), Regional Insights and Forecast From 2025 To 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

INSULIN INJECTION PEN MARKET OVERVIEW

The global Insulin Injection Pen market is anticipated to expand from USD 6.21 billion in 2025 to USD 7.26 billion in 2026, and further to USD 29.61 billion by 2035, growing at a CAGR of 16.91% during 2025–2035.

The insulin injection pen market is projected to experience a stunning increase. Novo Nordisk A/S announced the anticipated release of Bluetooth-enabled smart Insulin injection Pens. Both time logs and insulin dosages can be recorded using the pen. Smart insulin pens were created with the intention of preventing unnecessary dosages, maintaining a systematic record of dosage, and converting dosage data into computer-based reports.

Along with Roche, Dexcom, and Glooko, the company is creating smart insulin injection pens. The Insulin injection Pen has gained popularity over the past 30 years due to its portability, usability, history of accurate usage, and reduced pain compared to injection. It has been noted that in 2017, the percentage of countries using insulin injection pens in high-, middle-, and low-income groups was 81%, 36%, and 13%, respectively. Insulin injection pens are anticipated to be replaced throughout the projection period by smart insulin injection pens, which may notify users of upcoming dosages and record your insulin usage.

Key Findings

COVID-19 IMPACT

Limitations and Drop in Trade Led to Market Decline

In individuals with COVID-19, diabetes has been directly linked to disease severity and mortality. This fact is supported by the rising morbidity and mortality rates that have been associated with inflammation, hypercoagulation, and weakened immune systems. Both hypoglycaemia and hyperglycaemia are indicators of worse outcomes in individuals who are hospitalised. To lessen the risk of severe COVID-19, individuals with diabetes and SARS-CoV-2 infection should strive for optimal glycaemic management. Both insulin and GLP-1RAs have demonstrated effective glucose-lowering and anti-inflammatory effects in diabetic patients and may be a viable treatment option to treat COVID-19 diabetic individuals who are asymptomatic and not in critical condition. To change the dosage of insulin or anti-diabetic medications and conduct strict glucose monitoring, customised therapies for diabetes management are now required.

The market for insulin injection pens was not significantly impacted by the COVID-19 pandemic. Patients who were already utilising injectable pens for a variety of medicines kept doing so throughout the pandemic. However, mobility limitations, closed borders, and a drop in overall trade damaged the supply chain for insulin injection pens. Patients with COVID-19 infection who underwent therapy have a greater risk of developing diabetes. Consequently, if the prevalence of diabetes rises, so will the need for injections.

LATEST TRENDS

Disposal and reusable insulin injection to Boost Market Growth

Traditionally, disposable, and reusable insulin pens come with different types of cartridges. Due to the increased prevalence of diabetes and several market participants who provide technologically sophisticated goods, the classic insulin pens are anticipated to grow in popularity during the forecasted period. For patients to quickly identify the type of insulin they are using, many brands offer pens that are color-coded and include various patterns. This shortens the administration period and makes them more portable than syringes and containers. Additionally, some recent versions come with a digital application that can help you recall when you last provided insulin and how much. 

• According to the International Diabetes Federation (IDF), around 36% of patients in middle-income countries now use insulin pens, while 81% in high-income countries rely on them, reflecting growing adoption of disposable and reusable pen devices.

• Bluetooth-enabled smart insulin pens are increasingly adopted, with approximately 40% of new product launches in Europe and North America featuring digital dose tracking and mobile app integration (according to U.S. FDA device reports, 2024).

•   
•   
  

  Download Free Sample to learn more about this report

    

INSULIN INJECTION PEN MARKET SEGMENTATION

By Type

Based on type; the insulin injection pen market is divided into Disposable Insulin Injection pen type, Reusable Insulin Injection Pen type.

In terms of product, disposal insulin injection pen market type is the largest segment.

By Application

Based on application; the insulin injection market is divided into Hospital & Clinic, Retail Pharmacies, online.

In terms of application, Hospital and Clinic is the largest segment of Insulin injection market.

DRIVING FACTORS

Increasing Demand from End-Use Industries to Enhance Market Growth

In recent decades, there has been a significant rise in the prevalence of chronic diseases. Multiple sclerosis, diabetes, osteoporosis, cardiovascular disease (CVD), and other illnesses demand for the administration of injectable medications on a daily or weekly basis. Due to the frequent drug administration, are the best choice for chronic disorders.

The latest industry standard for injectable medicine delivery devices is the insulin injection pen. Their ease of use, dependability, and capacity to be provided by the patient alone without the assistance of a doctor have caused their popularity to grow. To effectively manage the expanding patient population and improve patient compliance with therapies, insulin injection pen technologies have come under more scrutiny as a result the rising prevalence of chronic diseases.

Technological Advancements in Biosimilars to Increase the Market Growth

The demand for biosimilars will be fuelled by numerous biologic compounds' upcoming patent expirations. The adoption of generic and biosimilar drugs is encouraged by insurance companies and governments. For instance, CVS Caremark, one of the largest prescription insurance providers in the US, has substituted branded injectable medications like Lantus by Sanofi and EpiPen by Mylan with their biosimilars Basaglar by Eli Lilly and Adrenaclick by Amedra Pharmaceuticals. Since many injectables used to treat chronic diseases are biologics, the insulin injection pen market is expected to expand as patents expire and government and insurance backing increases.

• Rising diabetes prevalence: WHO reports over 537 million adults worldwide living with diabetes in 2023, driving insulin pen demand, particularly in North America, which accounts for 35% of total global usage.

• Technological advancement in biosimilars: According to U.S. Centers for Medicare & Medicaid Services (CMS), over 50% of insulin prescriptions in the U.S. now utilize biosimilar alternatives, supporting growth in insulin pen adoption due to insurance and government backing.

RESTRAINING FACTORS

High Risk of Hyperglycaemia Lead to Decrease the Market Growth

 The primary deterrents for using insulin injection pens are fear of needle sticks and harm. Therefore, there are many needle-free devices that have the extra benefit of not causing needle fear, which is a major barrier to the increased use of injectable medication therapies. Children's and adults' non-complacency is mostly related to the discomfort of the daily injections and the demands of long-term therapy. Additionally, because the dose cannot be controlled, insulin injection pen therapy is seen to result in hyperglycaemia in certain patients. Due to their capability to execute automated insulin suspension and reduce the danger of hypoglycaemia, insulin pumps have therefore replaced insulin injection pens in the treatment of diabetes. 

• Needle fear and hyperglycaemia: Surveys from the American Diabetes Association (ADA) indicate 25–30% of patients prefer alternative delivery devices like insulin pumps due to fear of needle sticks and risk of hyperglycaemia.

• Dose control limitations: Clinical studies in Europe show that approximately 20% of insulin pen users experience dosing inaccuracies leading to treatment complications.

•   
•   
  Download Free Sample to learn more about this report

    

INSULIN INJECTION PEN MARKET REGIONAL INSIGHTS

North America to Dominate the Market due to technological advancement

 North America is expected to dominate the global share of insulin injection pens market during the forecast period owing to the higher prevalence of diabetes as well as higher healthcare spending on the treatment of diabetes. Moreover, technological advancements in insulin pens are projected to boost the adoption of insulin pens in North America. Europe is anticipated to register a considerable CAGR owing to the gradual shift of patients to self-care instead of dependency. Asia Pacific is projected to register a comparatively higher CAGR owing to the higher patient pool of diabetic patients. Moreover, the implementation of intense market penetration strategies by major market players is anticipated to lead to increased adoption of insulin pens in the region during the forecast period.

KEY INDUSTRY PLAYERS

The research provides a full overview of the analysis of the major surface of insulin injection market industry aspects, including sales value, sales volume, market revenue, and demand size, as well as sales growth, pricing analysis, and changing regional market growth factors. The market participants and their respective positions within the industry are discussed in the report. Data is being collected and made available through proper research, mergers, technical advancement, growing production facilities, and cooperation. The study on materials contains information on producers, locations, types, applications, sales channels, and distributors.

• Eli Lilly (U.S.): Supplies over 50 million insulin pen units annually, focusing on smart and reusable devices.

• Novo Nordisk (Denmark): Manufactures over 60 million pens per year, including Bluetooth-enabled models for digital dose tracking.

List of Top Insulin Injection Pen Companies

• Eli Lilly (U.S.)
• Novo Nordisk (Bagsvaerd, Denmark
• Sanofi (France)
• BD (U.S.)
• Ypsomed Holding (Switzerland)
• Dongbao (China)
• Owen Mumford (U.S.)
• Ganlee (China)
• Delfu (UK.)

REPORT COVERAGE

The report helps in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns and so on. Includes a chapter on the impact of covid-19 pandemic on the market. The data is further compiled & validated through various market estimation & data validation methodologies. The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The report also provides information about the top-winning strategies implemented by industry players.